RegenXBio gets FDA support for Hunter syndrome gene therapy's accelerated review filing—in 2024

It’s going to be a long wait, but RegenXBio is already waving a flag to show that the Hunter syndrome gene therapy RGX-121 is headed for an accelerated approval request at the FDA.